Plain-English translation of NCT06612580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new type of imaging scan called PET/CT. The scan uses a special tracer — a tiny amount of radioactive material — that travels through your body and attaches to prostate cancer cells, helping doctors see where cancer may be located. This is the first time this particular scan is being tested in patients.
Doctors need better ways to detect prostate cancer and understand which areas of the cancer are most dangerous. This new imaging treatment combines two approaches: it targets cancer cells directly and also looks for areas where oxygen is low, which often indicates aggressive cancer.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the tracer medication through an IV, followed by a PET/CT imaging scan to see how the tracer moves through your body and attaches to cancer cells. The researchers will monitor your safety and use the images to evaluate how well this new scan works for detecting prostate cancer. The entire study involves one visit with imaging and safety follow-up.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
First Affiliated Hospital of Fujian Medical University
Enrollment target
~10 participants
Started
September 2024
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weibing Miao, MD
First Affiliated Hospital of Fujian Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.